The Dup15q Alliance is aware of the recent release by the FDA regarding Clonazepam Orally Disintegrating Tablets USP by Endo USA due to potential product carton strength mislabeling. Ongoing investigation identified the possibility that the affected clonazepam product lot numbers contain a limited number of cartons printed incorrectly. The blister strips and tablets inside the product pack reflect the correct strength for the lot. Children and adults who inadvertently consume a higher dose of clonazepam could be at increased risk for the adverse events of significant sedation, confusion, dizziness, diminished reflexes, ataxia, and hypotonia. For more information about this recall, including the affected clonazepam product lot numbers, click this link: https://www.fda.gov/safety/
SOAR Webinar
**At this time, the SOAR study has reached capacity for conference participation. However, there still may be opportunities for research participation at the family conference due to cancellations or addition of other opportunities. If you would like to be placed on a...
